These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10466627)

  • 1. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease.
    Takenaka T; Qin G; Brady RO; Medin JA
    Hum Gene Ther; 1999 Aug; 10(12):1931-9. PubMed ID: 10466627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.
    Takenaka T; Hendrickson CS; Tworek DM; Tudor M; Schiffmann R; Brady RO; Medin JA
    Exp Hematol; 1999 Jul; 27(7):1149-59. PubMed ID: 10390190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
    Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preselective gene therapy for Fabry disease.
    Qin G; Takenaka T; Telsch K; Kelley L; Howard T; Levade T; Deans R; Howard BH; Malech HL; Brady RO; Medin JA
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3428-33. PubMed ID: 11248095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector.
    Medin JA; Tudor M; Simovitch R; Quirk JM; Jacobson S; Murray GJ; Brady RO
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7917-22. PubMed ID: 8755577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
    Yoshimitsu M; Higuchi K; Ramsubir S; Nonaka T; Rasaiah VI; Siatskas C; Liang SB; Murray GJ; Brady RO; Medin JA
    Gene Ther; 2007 Feb; 14(3):256-65. PubMed ID: 16929352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
    Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrovirus-mediated transfer of human alpha-galactosidase A gene to human CD34+ hematopoietic progenitor cells.
    Takiyama N; Dunigan JT; Vallor MJ; Kase R; Sakuraba H; Barranger JA
    Hum Gene Ther; 1999 Dec; 10(18):2881-9. PubMed ID: 10609650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease.
    Sugimoto Y; Aksentijevich I; Murray GJ; Brady RO; Pastan I; Gottesman MM
    Hum Gene Ther; 1995 Jul; 6(7):905-15. PubMed ID: 7578409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
    Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N
    J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
    Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
    Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for Fabry disease.
    Siatskas C; Medin JA
    J Inherit Metab Dis; 2001; 24 Suppl 2():25-41; discussion 11-2. PubMed ID: 11758676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease.
    Ziegler RJ; Li C; Cherry M; Zhu Y; Hempel D; van Rooijen N; Ioannou YA; Desnick RJ; Goldberg MA; Yew NS; Cheng SH
    Hum Gene Ther; 2002 May; 13(8):935-45. PubMed ID: 12031126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
    Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
    Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry disease.
    Li C; Ziegler RJ; Cherry M; Lukason M; Desnick RJ; Yew NS; Cheng SH
    Mol Ther; 2002 Jun; 5(6):745-54. PubMed ID: 12027559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.
    Miyamura N; Araki E; Matsuda K; Yoshimura R; Furukawa N; Tsuruzoe K; Shirotani T; Kishikawa H; Yamaguchi K; Shichiri M
    J Clin Invest; 1996 Oct; 98(8):1809-17. PubMed ID: 8878432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity.
    Ramsubir S; Yoshimitsu M; Medin JA
    Mol Ther; 2007 Jun; 15(6):1174-81. PubMed ID: 17387334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
    Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.